Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q1 2026 Earnings Presentation
21 slides from Sanara Medtech's earnings presentation, May 12, 2026
Slide 1: Sanara MedTech
Sanara MedTech Nasdaq: SMTI April 16, 2026
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Growth-Oriented Technologies in the Operating Room
Growth-Oriented Technologies in the Operating Room A medical technology company with innovative products focused on the treatment of surgical wounds in the operating room setting 51% $103M >4,000 $103M 7-Year Net 2025 Net Revenue Contracted Hospitals Revenue CAGR $17M ($0.4M) $183M 2025 Adjusted EBI
Slide 4: Investment Highlights
Investment Highlights Multi-year history of high revenue growth in the surgical OR setting, with commercial scale Entered 2026 as a ‘pure play’ surgical business with a compelling margin profile and not subject to reimbursement risk Key technologies represent differentiated solutions, advancing the
Slide 5: Consistent High Growth in the Surgical Market
Consistent High Growth in the Surgical Market Net Revenue in millions $ $103.1 $86.7 $65.0 $45.8 $24.1 $15.6 $11.8 $5.8 2018 2019 2020 2021 2022 2023 2024 2025 5 © 2026 Sanara MedTech Inc. All Rights Reserved.
Slide 6: A New Chapter as a 'Pure-Play' Surgical Business
A New Chapter as a ‘Pure-Play’ Surgical Business Sanara MedTech: Pre-2026 Sanara MedTech: 2026 and Beyond • Focused on multiple sites of care • Singular focus on the surgical operating • Multiple segments, with a capital- room intensive, pre-revenue business (THP) • Single business segment • Mix of
Slide 7: Key Surgical Technologies
Key Surgical Technologies Targeting Large Addressable Market Opportunities Focused on surgical technologies in high-margin categories where we can achieve and sustain market leadership in the treatment of surgical wounds Hydrolyzed Collagen Technology Antimicrobial Irrigation Technology BioAdhesive
Slide 8: Surgical Portfolio
Surgical Portfolio Engineered for Growth Key Surgical Technologies Additional Surgical Products CellerateRX® Surgical Powder • Unique hydrolyzed collagen in the OR; market leader • >20 published clinical studies • Contracted on most national GPOs and IDNs BIASURGE® Advanced Surgical Solution • Only
Slide 9: Clinical Evidence
Clinical Evidence Key Products Supported by Expanding Portfolio of Peer-Reviewed Studies1 Pre-Clinical Spine Advances in Wound Care JSM Neurosurgery and Spine Hydrolyzed Collagen Powder Dressing Improves Wound The Use of Sterile Bovine Type 1 Hydrolyzed Collagen to Inflammation, Perfusion, and Break
Slide 10: Sales and Distribution Network
Sales and Distribution Network Proven, Efficient Model Built for Scale Sales & Distribution Overview 1 Heat Map of Distributor Agreements1 40 >400 Field Sales Distributor Representatives Agreements >4,000 >1,400 Hospitals Hospital Contracted / Approved Customers 0 24 10 1. As of 12/31/25. © 2026 San
Slide 11: Key Drivers To Grow and Scale Surgical Portfolio
Key Drivers To Grow and Scale Surgical Portfolio Capitalize on Contracted Hospital Opportunity Increase Number of Surgeons within Active Hospitals • Add new hospital customers from the 4,000+ facilities • Add new surgeon users within the 1,400+ facilities we currently where our products are contract
Slide 12: FY25 Financials & FY26 Guidance
FY25 Financials & FY26 Guidance 2025 2026 FY25 Results FY26 Revenue Guidance • Net revenue: $103.1 • Net revenue: $116 to $121 million • Increase of 19% y/y • Increase of ~13% to 17% y/y • Cash: $16.6 million1 • Long-term debt: $46.0 million1 12 1. As of 12/31/25 © 2026 Sanara MedTech Inc. All Right
Slide 13: 2026 Priorities
2026 Priorities Drive strong sales growth through expansion of internal salesforce and distributor partners Activate Vizient contract and expand BIASURGE ® access to ~1,800 newly contracted facilities R&D product enhancement projects Clinical research investment across all three key surgical technol
Slide 14: Appendix
Appendix ee . Sanara - Fe MedTech ° ° oe e e e ee i a a cd
Slide 15: CellerateRX® Surgical Powder
CellerateRX® Surgical Powder A unique hydrolyzed collagen in the operating room • Indicated for the management of acute and chronic wounds • Hydrolyzed – collagen fragments do not have to be broken down by the body before use • Supported by >20 published clinical studies • >4,000 approved / contract
Slide 16: BIASURGE® Advanced Surgical Solution
BIASURGE® Advanced Surgical Solution A no-rinse antimicrobial surgical irrigation solution • Indicated for use in mechanical cleansing and removal of debris, including microorganisms, from surgical wounds • Eliminates >6 logs of bacteria microbes through mechanical cleansing • Supported by pre-clini
Slide 17: OsStic BioAdhesive Advanced Bone Fixation
OsStic BioAdhesive Advanced Bone Fixation Expected to be the first synthetic injectable bone bioadhesive in the U.S. • FDA Breakthrough Device Designation received • Exclusive U.S. marketing, sales, and distribution rights secured January 2025 • Targets >100,000 periarticular fractures annually – la
Slide 18: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this presentation, including Adjusted EBITDA. The Company’s management
Slide 19: Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA (Unaudited)
Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA (Unaudited) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Net income (loss) from continuing operations $ (1,107,310) $ 934,703 $ (393,124) $ (1,937,583) Adjustments: Interest expense 1,833
Slide 20: Consolidated results of operations (surgical business)
Consolidated results of operations (reflecting our surgical business) for the periods indicated below (Unaudited except for full fiscal years ended December 31, 2025, 2024, and 2023) (1) Selling, general and administrative expense of $90,293 was reclassified and is now reflected as discontinued oper
Slide 21: Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA
Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA for the periods indicated below (Unaudited) (1) Depreciation expense of $5,461 and $7,021 was reclassified in the first and second quarters of 2025, respectively, and is therefore not reflected as discontinued operatio